Background: Abemaciclib (abema), a cyclin D kinase 4 & 6 inhibitor, has single-agent activity and an acceptable safety profile when dosed continuously in patients with previously treated metastatic NSCLC (NCT01394016). In tumor models, CDK inhibition induces an escape pathway involving PI3kinase (PI3K) and abema induces synergistic immune activation with checkpoint inhibitors. We report on activity and safety of abema plus LY3023414 (LY), a PI3K/mTOR dual inhibitor, and abema plus pembrolizumab (pembro), an anti-PD-1 antibody, in an ongoing Phase 1b open-label, 3 þ 3 multicenter trial of previously treated advanced NSCLC (NCT02079636). Methods: For escalation, Abema [100, 150 mg, or 200 mg (cohort D only)] was given orally on a continuous schedule every 12 hours (q12h) with LY at 100, 150, or 200 mg q12h (cohort D) or with pembro at 200 mg I.V. infusion q3 weeks (cohort E). Confirmatory cohorts were given 150 mg abema with 150 mg LY or 200 mg pembro. Pts were treated until progression or other discontinuation criteria were met. Responses were evaluated with RECIST v1.1. Safety assessments followed the NCI-CTCAE v4.0. Results: As of 01-Mar-2017, cohort D (n ¼ 29) had 62.1% males, 37.9% 65 years of age, median # prior systemic therapies¼3; 86.2% stage IV; 72.4% adenocarcinoma; 62.1% ECOG PS ¼ 1. 9 pts (31%) had stable disease (SD), 3 pts had progressive disease (PD), and the status for the remaining 17 pts was unknown or under evaluation. There were 3 deaths unrelated to study drug (2 disease related and 1 stroke). 24/29 pts had a treatment emergent, related AE (TRAE), 10/24 had a Grade 3/4 TRAE. Any grade TRAEs (>30% pts) were nausea (51.7%), diarrhea (51.7%), vomiting (41.4%), and decreased appetite (31%). Cohort E had 19 pts entered (42.1% male, 42.1% 65 years of age, median # prior systemic therapies¼2; 52.6% stage IV; 89.5% adenocarcinoma; 57.9% ECOG PS ¼ 1). 8 pts (42.1%) had SD, 1 had PD, and the status for the remaining 10 pts was unknown or under evaluation. There were 3 disease related deaths. 15/19 pts had a TRAE, 5/15 had a G3/4 TRAE. Any grade TRAEs (>30% pts) were fatigue (n ¼ 47.4%) and diarrhea (36.8% Background: Exposed phosphatidylserine (PS) in the tumor microenvironment is highly immunosuppressive. Bavituximab targets PS and repolarizes M2 macrophages to M1 resulting in production of pro-inflammatory cytokines such as IFN-c and IL-12, maturation of dendritic cells, and tumor specific cytotoxic T lymphocyte immunity. In a prior blinded Phase II trial in 2 nd -line nonsquamous NSCLC, bavituximab þ docetaxel was well-tolerated and demonstrated 60% improvement (11.7 vs 7.3 months) in median overall survival (mOS) (HR, 0.66; P ¼ 0.11) compared to control. Methods: 597 patients with Stage IIIb/IV nonsquamous NSCLC that progressed on platinum-doublet chemotherapy were randomized 1:1 to receive up to six 21-day cycles of docetaxel in combination with weekly 3 mg/kg bavituximab (BþD) or placebo (D) until progression or toxicity. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. 
